Blood Testing Companies Report Mixed Earnings; Natera Posts Wider-Than-Expected Loss

on Nov. 6, according to Investor’s Business Daily, blood testing companies Natera and Guardant Health released their third-quarter earnings reports, with both raising full-year revenue guidance. Previously, investors were disappointed by weak sales of peer Grail's cancer detection product Galleri.

Natera reported a loss per share of $0.42, exceeding the market expectation of $0.29; revenue was $794 million, above the forecasted $708 million. Guardant Health reported a loss per share of $0.29, lower than the expected $0.31; revenue was $361 million, above the expected $351 million.

The report also noted that prostate cancer testing volume at cancer diagnostic company Veracyte was weak; lab research tools company 10x Genomics reported a third-quarter loss per share of $0.15 and revenue of $150.7 million, both performing better than market expectations.